|
|
Post by mnholdem on Oct 30, 2015 10:33:31 GMT -5
Who was it that posted their thought this week that the first sales milestone may be $50M sales... the same as the sales milestone listed in the Deerfield agreement?
It's entirely possible that the $250M payment will be made when Afrezza reaches $50M sales. $50M may be considered proof of marketability.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 30, 2015 10:42:34 GMT -5
Who was it that posted their thought this week that the first sales milestone may be $50M sales... the same as the sales milestone listed in the Deerfield agreement? It's entirely possible that the $250M payment will be made when Afrezza reaches $50M sales. $50M may be considered proof of marketability. and a block buster so called Lantus had sales of $60 million the first year? so $50 million is probable. lantus sales : mnkd.proboards.com/thread/1853/lantus-numbers#ixzz3q4ATPjos |
|
|
|
Post by seanismorris on Oct 30, 2015 11:36:30 GMT -5
How about an acquisition of an Israeli company (tax inversion) to lower the tax rate and that has cash flow to fund joint operations. Funded by the Mann Group, which is dilutive but removes the uncertainty of MannKinds survival.
The result: a company with lower costs, cash flow, and an enormous tax credit from MannKinds years of losses.
The "tax inversion" wouldn't be denied because MannKinds income (at this point) is basically nonexistent.
|
|
|
|
Post by lakers on Oct 30, 2015 13:50:36 GMT -5
 www.sec.gov/Archives/edgar/data/899460/000119312514406347/d783199dex101.htm1.70 “MAA” shall mean a New Drug Application as defined in Title 21 of the U.S. Code of Federal Regulations, Section 314.80, et seq., or comparable filing with any Regulatory Authority in any country or jurisdiction in the Territory other than the United States, and all amendments and supplements thereto, which is filed with the FDA, including all documents, data, and other information concerning a pharmaceutical product which are necessary for gaining Marketing Approval in the Territory. Item #4 is neither mfgr, sales, Regulatory approval. It could be for dev. |
|
|
|
Post by mdcenter61 on Oct 30, 2015 14:51:21 GMT -5
So the way I would read that, Lakers, the milestone payments for sales would not be payable until Annual sales reach a certain amount, rather than cumulative sales. If that first milestone is $50 million in annual sales, we are a ways from growing to that point considering quarterly sales right now are around $4 to $5 million. We need to triple where we are right now and maintain for a year. It means that until we get to that pace, this year's revenues and possibly next year's don't factor into the equation other than laying the base. I also wonder if annual sales are calculated on an calendar basis or if they look at fiscal periods for the lookback.
|
|
|
|
Post by dreamboatcruise on Oct 30, 2015 15:13:44 GMT -5
Who was it that posted their thought this week that the first sales milestone may be $50M sales... the same as the sales milestone listed in the Deerfield agreement? It's entirely possible that the $250M payment will be made when Afrezza reaches $50M sales. $50M may be considered proof of marketability. I'm pretty certain it is $250M revenue. |
|
|
|
Post by chuck on Oct 30, 2015 15:19:39 GMT -5
Sales milestone payments are $650m in aggregate, beginning at annual sales of $250m. There are six sales thresholds. Each threshold is annual sales for a "Calendar Year".
|
|
|
|
Post by lakers on Oct 30, 2015 17:10:16 GMT -5
Sales milestone payments are $650m in aggregate, beginning at annual sales of $250m. There are six sales thresholds. Each threshold is annual sales for a "Calendar Year". You read correctly. Other keywords are "first exceed", "in Territory". |
|
|
|
Post by lakers on Oct 30, 2015 19:35:12 GMT -5
1.108 “Terminated Country” shall have the meaning set forth in Section 13.1. 1.109 “Territory” shall mean all countries of the world, excluding any Terminated Country. 13.1 Partial Termination. In case of termination of this Agreement, not in its entirety, but with respect to only a particular country (other than the United States) by MannKind pursuant to clause (y) of Section 12.2(a) or with respect to only a particular country or region by Sanofi pursuant to Section 12.3(a) (a “Partial Termination” and each country or region in which such Partial Termination occurs, a “Terminated Country”), then the effects of termination described under this Article 13 shall only apply to the Terminated Country, and this Agreement shall remain in full force and effect in accordance with its terms in all countries of the Territory other than the Terminated Country. 12.3 Additional Sanofi Termination Rights. (a) If, at any time on or after January 1, 2016, Sanofi determines in good faith that Commercialization of Product is no longer economically viable in the United States, then Sanofi may terminate this Agreement in its entirety upon delivery of at least ninety (90) days’ prior written notice to MannKind. In addition, at any time on or after January 1, 2016, upon delivery of at least six ( 6) months’ prior written notice to MannKind, Sanofi shall have the right to terminate this Agreement for any reason (a) in its entirety, or (b) on a country-by-country basis other than with respect to the United States; provided, however, that if Sanofi terminates this Agreement under this Section 12.3(a) in each of […***…], then Sanofi shall terminate this Agreement with respect to all countries of the European Union. For purposes of clarity, Sanofi shall have no right to terminate this Agreement with respect to only the United States under this Section 12.3(a). www.sec.gov/Archives/edgar/data/899460/000119312514406347/d783199dex101.htm |
|
|
|
Post by mnholdem on Nov 2, 2015 9:08:58 GMT -5
MannKind Corporation to Hold 2015 Third Quarter Financial Results Conference Call on November 9, 2015
VALENCIA, Calif., Nov. 2, 2015 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2015 third quarter financial results on Monday, November 9, 2015 and its management will host a conference call to discuss the third quarter financial results and other Company developments at 5:00 PM (Eastern Time) on November 9, 2015.
Presenting from the Company will be its Chief Executive Officer, Hakan Edstrom and Chief Financial Officer, Matthew Pfeffer.
To participate in the live call by telephone, please dial (800) 708-4539 or (847) 619-6396 and use the participant passcode: 3859 3130. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at www.mannkindcorp.com.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 3859 3130#. A replay will also be available on MannKind's website for 14 days.
Press release: files.shareholder.com/downloads/AMDA-22AIJ9/954423346x0x858055/30d2d95a-74d2-4762-a7bb-fbc8d0ad2966/MNKD_News_2015_11_2_General_Releases.pdf
---
The PR confirms #2 in the first post of this thread by lakers, that the earnings conference date will be Nov. 9, 2015
As for #1, that the BoD will "convene in second half of Nov 2015 to decide on important matters," we may never know since MannKind has never been in the habit of publishing minutes from its BoD meetings, although it's possible that Hakan or Matt will confirm this at some time in the future.
|
|
|
|
Post by peppy on Nov 2, 2015 9:55:21 GMT -5
|
|
|
|
Post by orlon on Nov 2, 2015 10:30:23 GMT -5
Maybe Hakan will discuss Sanofi's Phase III results of lexilan for type 2 diabetics, and why and how he, as CEO, is letting Sanofi screw over his company. |
|
|
|
Post by mssciguy on Nov 2, 2015 10:39:53 GMT -5
orlon I am more concerned about the non-stop assault on share price and the total failure of public relations with Wall Street types which I previously assumed was part of the CEO's job. Look at Lilly for example, despite the huge revenue shortfalls last year and a pipeline that has produced almost nothing of value for the past 5 years, the CEO shmoozes with the CNBC folks and others mingle with sell side analysts and provide some hype for the company. I have watch this for years. If Al, Hakan, and Matt don't want to shmooze, why not hire someone to do it? And also hire a securities lawyer to press SEC on the non-stop naked shorting assault. What has been happening lately is beyond ridiculous. Enjoy your week y'all same stuff, different day...  illusory stock price but lately I am very tempted to daytrade this, it's been a real yo-yo lately.
|
|
|
|
Post by kdaddyfresh2000 on Nov 2, 2015 10:46:58 GMT -5
Maybe Hakan will discuss Sanofi's Phase III results of lexilan for type 2 diabetics, and why and how he, as CEO, is letting Sanofi screw over his company. [br After he takes a question from Goldman's Jay Olson because, you know, you have to please your lying critics. Oh wait, maybe you shouldn't but do it anyway for some inexplicable reason. |
|
|
|
Post by peppy on Nov 2, 2015 10:50:34 GMT -5
killer price action on heavy volume this morning. A big seller. |
|
illusory stock price but lately I am very tempted to daytrade this, it's been a real yo-yo lately.